More recently, they reported safety and efficacy of HD IL-2 treatment in patients who had previously received anti-PD1 therapy and then progressed, (including both melanoma and mRCC patients) with outcomes similar to patients treated with IL-2 alone as first line therapy [24]. This evidence concerns the gene IL2 and melanoma.